These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 30764058)

  • 21. Challenges Related to Glycemic Control in Type 2 Diabetes Mellitus Patients.
    Kheirandish M; Mahboobi H; Yazdanparast M; Kamal MA
    Curr Drug Metab; 2017; 18(2):157-162. PubMed ID: 28093996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exenatide.
    Keating GM
    Drugs; 2005; 65(12):1681-92; discussion 1693-5. PubMed ID: 16060703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stabilizing effect of exenatide in a patient with C-peptide-negative diabetes mellitus.
    Paisley AN; Savage MW; Wiles PG
    Diabet Med; 2009 Sep; 26(9):935-8. PubMed ID: 19719716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exenatide: a new option for the treatment of type 2 diabetes.
    Yoo BK; Triller DM; Yoo DJ
    Ann Pharmacother; 2006 Oct; 40(10):1777-84. PubMed ID: 16985091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus].
    Reuter H; Erdmann E
    Dtsch Med Wochenschr; 2007 Mar; 132(11):571-4. PubMed ID: 17342635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
    Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
    Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Medication of the month... Exenatide (Byetta) incretinomimetic in the treatment of type 2 diabetes after failure and as add-on therapy to oral agents].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2008 Mar; 63(3):158-65. PubMed ID: 18561773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
    Nauck MA; Meier JJ
    Regul Pept; 2005 Jun; 128(2):135-48. PubMed ID: 15780433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives.
    Edavalath M; Stephens JW
    Patient Prefer Adherence; 2010 Mar; 4():61-8. PubMed ID: 20361006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review of exenatide: optimizing glycemic control and associated cardiovascular risk factors in type 2 diabetes.
    Htike ZZ; Khunti K; Davies M
    Diabetes Ther; 2012 Nov; 3(1):1-16. PubMed ID: 22422427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A 24-week, prospective, randomized, open-label, treat-to-target pilot study of obese type 2 diabetes patients with severe insulin resistance to assess the addition of exenatide on the efficacy of u-500 regular insulin plus metformin.
    Distiller LA; Nortje H; Wellmann H; Amod A; Lombard L
    Endocr Pract; 2014 Nov; 20(11):1143-50. PubMed ID: 24936555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exenatide once weekly: clinical outcomes and patient satisfaction.
    Jose B; Tahrani AA; Piya MK; Barnett AH
    Patient Prefer Adherence; 2010 Sep; 4():313-24. PubMed ID: 20859458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks.
    Kadowaki T; Namba M; Imaoka T; Yamamura A; Goto W; Boardman MK; Sowa H
    J Diabetes Investig; 2011 Jun; 2(3):210-7. PubMed ID: 24843486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus.
    Bond A
    Proc (Bayl Univ Med Cent); 2006 Jul; 19(3):281-4. PubMed ID: 17252050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy.
    George RE; Joseph S
    Saudi Pharm J; 2014 Nov; 22(5):403-10. PubMed ID: 25473328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes.
    Nielsen LL; Okerson T; Holcombe J; Hoogwerf B
    J Diabetes Sci Technol; 2008 Mar; 2(2):255-60. PubMed ID: 19885351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exenatide Effects on Cardiometabolic Risk and Weight in Adolescents with Morbid Obesity and Type 2 Diabetes Mellitus: Two Case Reports.
    Censani M; Chin VL; Fennoy I
    J Obes Weight Loss Medicat; 2015; 1(1):. PubMed ID: 27182560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes.
    Odegard PS; Desantis A
    Diabetes Metab Syndr Obes; 2009 Jul; 2():135-44. PubMed ID: 21437127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypoglycemia Abrogates the Vascular Endothelial Protective Effect of Exenatide in Type 2 Diabetes Mellitus.
    Torimoto K; Okada Y; Tanaka Y
    Diabetes Ther; 2019 Jun; 10(3):1127-1132. PubMed ID: 30875066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of exenatide in a morbidly obese patient with type 2 diabetes.
    Kishimoto M; Noda M
    Diabetes Ther; 2014 Jun; 5(1):323-32. PubMed ID: 24442463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.